Previously Mel served at ASX listed Panbio and ImpediMed where he managed diagnostics, therapeutics and medical device businesses.
Mel served at Alchemia as chairman and as a director at ImpediMed Limited and Campbell Brothers and Benitec.
He also worked at healthcare/biotechnology companies as a chairman of Peptech and non-executive director of Domantis
Genetic Technologies Sid Hack chairman said Mel’s knowledge in the breast cancer diagnostics market in North America will help to accelerate the company’s cancer diagnostics business in the US.
